MARKET

CELC

CELC

Celcuity
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.81
+0.08
+0.82%
Closed 16:00 06/01 EDT
OPEN
9.66
PREV CLOSE
9.73
HIGH
10.08
LOW
9.36
VOLUME
20.70K
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
4.030
MARKET CAP
100.64M
P/E (TTM)
-12.9454
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CELC stock price target is 13.50 with a high estimate of 16.00 and a low estimate of 11.00.

EPS

CELC News

More
Celcuity Q1 EPS $(0.170), Inline
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.170) per share which met the analyst consensus estimate. This is a 6.25 percent decrease over losses of $(0.160) per share from the same period last year.
Benzinga · 05/07 20:03
Celcuity Reports First Quarter 2020 Financial Results and Recent Business Highlights
Significant progress made in development of new, highly precise diagnostics using proprietary CELsignia platform Expect to announce new clinical trial collaborations with pharmaceutical companies and trial ...
ACCESSWIRE · 05/07 20:00
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc.
Benzinga · 05/03 12:46
Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call
ACCESSWIRE · 04/23 20:40
The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.)
Benzinga · 04/17 11:35
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 04/08 11:53
Here's Why We're Not Too Worried About Celcuity's (NASDAQ:CELC) Cash Burn Situation
Simply Wall St. · 04/07 14:23

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About CELC

Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.
More

Webull offers kinds of Celcuity Inc stock information, including NASDAQ:CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions.